Comparison of high flow nasal cannula oxygen and conventional oxygen therapy on ventilatory support duration during acute-on-chronic respiratory failure: study protocol of a multicentre, randomised, controlled trial. The ‘HIGH-FLOW ACRF’ study

Jean-Damien Ricard,1,2,3 Fadia Dib,4,5,6 Marina Esposito-Farese,4,5 Jonathan Messika,1,2,3 Christophe Girault,7,8 the REVA network

ABSTRACT

Introduction This study protocol describes a trial designed to investigate whether high-flow heated and humidified nasal oxygen (HFHO) therapy in patients with hypercapnic acute respiratory failure (ARF) reduces the need of non-invasive ventilation (NIV).

Methods and analysis This is an open-label, superiority, international, parallel-group, multicentre randomised controlled two-arm trial, with an internal feasibility pilot phase. 242 patients with hypercapnic ARF requiring NIV admitted to an intensive care unit, an intermediate care or a respiratory care unit will be randomised in a 1:1 ratio to receive HFHO or standard oxygen in between NIV sessions. Randomisation will be centralised and stratified by centre and pH at admission (pH ≤7.25 or >7.25). The primary outcome will be the number of ventilator-free days (VFDs) and alive at day 28 postrandomisation. The secondary outcomes will encompass parameters related to the VFDs, comfort and tolerance variables, hospital length of stay and mortality. VFDs at 28 days postrandomisation will be compared between the two groups by Wilcoxon-Mann-Whitney two-sample rank-sum test in the intention-to-treat population. A sensitivity analysis will be conducted in the population of patients for whom the criteria of switching from NIV to spontaneous breathing, or conversely, are not strictly verified.

Ethics and dissemination The protocol has been approved by the Comité de Protection des Personnes (CPP) Sud-Ouest & Outre-Mer IV (ref CPP17-049a/2017-A01830-53) and will be carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. A trial steering committee will oversee the progress of the study. Findings will be disseminated through national and international scientific conferences, and publication in peer-reviewed journals.

Trial registration number NCT03406572.
failure (ARF) is a frequent cause of intensive care unit (ICU) hospitalisation.

Non-invasive ventilation (NIV) is the first-line ventilatory treatment for hypercapnic ARF. Its use has increased in hypercapnic ARF during the last two decades. Success of NIV increases with experience. It is applied intermittently or semicontinuously, that is, periods of spontaneous breathing (SB) with standard oxygen (O₂) are interspersed between each NIV session. Depending on the severity of the respiratory failure and patient’s tolerance of the technique, length of NIV sessions may vary considerably. Figures on the total amount of NIV received during the first 24 hours vary between 7 and 20 hours. This means that patients may spend a noticeable amount of time with standard O₂ alone during the acute phase of their respiratory failure. Standard O₂ has several drawbacks that may limit the benefit of intermittent NIV in hypercapnic ARF: (1) a limited gas flow which is well below the patient’s inspiratory flow rate, (2) a limited capacity and efficiency of oxygenation with non-controlled inspired fraction of oxygen (FiO₂), hence with a risk of excessive oxygen and induced hypercapnia and (3) cold and dry gas leading to discomfort and under-humidification of the airways and tracheobronchial secretions. Therefore, the benefits in terms of work of breathing and CO₂ removal resulting from NIV sessions could be rapidly lost during the standard O₂ periods.

Recently, the use of high-flow heated and humidified nasal oxygen therapy (HFHO) has gained enthusiasm among intensivists to manage ARF. HFHO delivers high flows (up to 70 L/min) of heated and humidified oxygen at a controlled and adjustable FiO₂ (0.21–1) that rapidly improve respiratory distress symptoms, oxygenation, respiratory comfort and outcome of patients with hypoxicemic ARF. Of note, all studies concur on the remarkable tolerance and comfort reported by patients treated with this technique. These unique features could overcome some of the drawbacks of standard O₂ during SB periods in patients with hypercapnic ARF.

Aims and hypotheses
The primary aim of this study is to determine if the use of HFHO, as compared with standard O₂, increases the number of ventilator-free days (VFDs) and alive at day 28, in patients with hypercapnic ARF requiring NIV. We hypothesise that HFHO applied during breaks of NIV could improve the management of ACRF in patients with chronic respiratory insufficiency and COPD, in comparison with standard O₂. The use of HFHO could sustain the benefits of NIV, thereby reducing the amount of NIV required. The key secondary aims are to evaluate the effect of HFHO compared with standard O₂ on:
- Parameters related to VFDs.
- Tolerance/comfort outcomes.
- Hospital length of stay.
- Mortality.
- Side effects.

METHODS AND ANALYSIS
Design overview
The ‘High Flow-ACRF’ study is an open-label, superiority, international, parallel-group, multicentre randomised controlled trial (RCT), in which patients with hypercapnic ARF are allocated in a 1:1 ratio to HFHO (experimental group) or to standard O₂ (control group). The trial design is summarised in table 1. We report the study protocol according to the SPIRIT (Standard Protocol Items: Recommendations for Interventionsal Trials) statement.7

In both groups, treatment will start after randomisation with a first NIV session of 2 hours, with arterial blood gas (ABG) measurement between 1 and 2 hours after initiating the NIV session (a delay of 15 min following the end of NIV session in drawing the ABG sample will be permitted). The NIV will be extended for those patients with a pH < 7.30. Patients will be assessed for their tolerance of NIV and their ability to switch to SB every 1 hour±30 min, except during sleep (22:00–8:00); they will be assessed for their tolerance of SB and for the need of resumption of NIV every 2 hours±30 min during the first 48 hours, and every 4 hours±1 hour thereafter.

To ensure that indications of NIV and invasive mechanical ventilation (IMV) are consistent across centres, NIV and IMV will be initiated and stopped in the same way in the two groups, using predefined criteria (box 1 and box 2). These criteria obtained consensus among participating study investigators, through a Delphi process (online appendix 1). Management of sequential NIV and oxygen therapy is described in online appendix 2. Patients will follow this cycle according to their allocated group, until weaning from NIV and subsequently from oxygen therapy (figure 1).

Study setting and population
Participants will be prospectively recruited among patients admitted to an ICU, an intermediate care or a respiratory care unit, in 26 centres belonging to the European REVA network (24 centres in France, 1 centre in Spain and 1 centre in Switzerland). Patients will be considered eligible for randomisation if they fulfil all of the inclusion criteria and none of the exclusion criteria, as defined in box 3. The key eligibility criteria include hypercapnic ARF and the need for ventilation support.

Interventions
Experimental group
In-between each NIV session, oxygen will be delivered using HFHO (AIRVO 2; Fisher & Paykel Healthcare, Auckland, New Zealand) with a flow set between 50 and 60 L/min, and a FiO₂ set to reach a targeted oxygen saturation (SpO₂) of 90% ≤ SpO₂ ≤ 94%.

Control group
NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. In-between each NIV session, oxygen will be delivered using low flow.
## Table 1  Schedule of enrolment, interventions and assessments

| Timepoint (days) | Study period | Enrolment | Allocation | Postallocation | Close-out |
|------------------|--------------|-----------|------------|----------------|-----------|
|                  |              | 0         | 0          | 0 to 28 maximum| 28 maximum|

### Enrolment

- Eligibility screen: X
- Express consent: X
- Allocation: X

### Interventions

- HFHO: X
- Standard O₂: X

### Assessments

#### Baseline variables

- Demographics: X
- Medical history: X
- Clinical examination: X
- Paraclinical examination (pH, SOFA score): X
- SAPS II score
- ECG–chest X-ray
- ACRF aetiology

#### Outcomes variables

- NIV duration: X
- HFHO or standard O₂ duration according to group allocation: X
- Intubation/reintubation: X
- Vital status: X
- VAS comfort after 1 hour of NIV resumption: X
- VAS dyspnoea after 1 hour of NIV resumption: X
- Likert scale for comfort after 1 hour of NIV resumption: X
- Likert scale for dyspnoea after 1 hour of NIV resumption: X
- VAS comfort after 2 hours of SB resumption*: X
- VAS dyspnoea after 2 hours of SB resumption*: X
- Likert scale for comfort after 2 hours of SB resumption*: X
- Likert scale for dyspnoea after 2 hours of SB resumption*: X
- Respiratory rate after 1 hour of NIV resumption: X
- Respiratory rate after 2 hours of SB resumption*: X
- Daily ABG: X
- Adverse events: X
- Hospital length of stay: X

#### Other variables

- Criteria for switching between NIV and SB: X
- Criteria to definitely stop NIV: X
- Criteria for intubation: X
- Discharge conditions: X

*Two hours of SB in the first 48 hours postrandomisation, and 4 hours thereafter.

ABG, arterial blood gas; ACRF, acute-on-chronic respiratory failure; HFHO, high flow heated and humidified nasal oxygen; NIV, non-invasive ventilation; SAPS II, simplified acute physiology score II; SB, spontaneous breathing; SOFA, sequential organ failure assessment; VAS, Visual Analogue Scale.
of standard \( O_2 \) to reach the same targeted \( SpO_2 \) of 90% ≤ \( SpO_2 \) ≤ 94%.

### Trial outcomes

#### Primary outcome

The primary outcome is the number of VFDs during the 28 days after randomisation.

It is defined as the number of days between randomisation and day 28 where the patient is alive and breathes without any ventilatory support (NIV or IMV) for at least 48 consecutive hours. Since the duration of follow-up of intervention trials addressing lung function in the critically ill is typically 28 days after study enrolment, and most of patients with ARF have either died or successfully weaned from ventilation by day 28, the 28-day landmark is chosen to determine VFDs.

#### Secondary outcomes

Please see table 2 for the full list of secondary outcomes.

#### Randomisation and sequence generation

The randomisation will be performed using CleanWEB, which is an online, central randomisation service running 24 hours/24. The randomisation groups will be indicated by the server and confirmed by email. In case of dysfunction of the server, the allocated randomisation group will be provided by phone by the coordinating office (Unité de Recherche Clinique, Bichat Hospital) and confirmed by email. The patient randomised by this method must be registered thereafter on CleanWEB server, before the next randomisation. The randomisation sequence will be computer generated in advance by a statistician of the coordinating office. It will be stratified by centre and pH at admission (pH≤7.25 or pH>7.25), with variable block sizes.

#### Allocation concealment

The number of experimental units per block will be kept confidential to avoid prediction of future patient’s allocation. Only the independent statistician and the computer programmer who will implement the sequence assignment in the secure electronic case report form (eCRF) will have access to the randomisation list. Allocation concealment will be ensured, as CleanWeb services will not release the randomisation code until the patient has been recruited into the trial.

#### Blinding

Due to the nature of the intervention, it is not feasible to blind study participants and investigators to whether the participants are allocated to the HFHO or \( O_2 \) group. The study statistician, however, will be blinded to the groups.

### Box 1: Criteria for switching between non-invasive ventilation (NIV) and spontaneous breathing (SB)

**Switch from NIV to SB will be required if at least two criteria are met:**

- Improvement in clinical signs of moderate to severe respiratory distress, that is, one or more of the following criteria:
  - Respiratory rate ≥ 25/min.
  - Use of accessory respiratory muscles (from severe to moderate, or moderate to absent).
  - Paradoxical abdominal motion (yes/no).
  - Regression of signs of respiratory encephalopathy (sleepiness and/or asterixis and/or confusion) (yes/no).

- Stabilisation or correction of hypercapnic respiratory acidosis on arterial blood gas (ABG), that is, pH ≥ 7.30 and decrease in \( PaCO_2 \) (alveolar carbon dioxide tension) of at least 10% as compared with baseline value (inclusion).

- Stabilisation or correction of hypoxemia: 88% ≤ \( SpO_2 \) (oxygen saturation) ≤ 92% and/or arterial oxygen tension (\( PaO_2 \)) ≥ 60 mm Hg (8 kPa) with FIO\(_2\) (inspired fraction of oxygen) < 0.5 under NIV.

- Intolerance to NIV (agitation and/or mask removal, and/or patient’s wish to interrupt session before).

**Switch from spontaneous breathing to NIV will be required if one of the following criteria, at least, is met:**

- Worsening in clinical signs of moderate to severe respiratory distress, that is, one or more of the following criteria:
  - Dyspnoea (increase of at least two points in the Visual Analogue Scale).
  - Respiratory rate > 25/min.
  - Use of accessory respiratory muscles (from absent to moderate, or moderate to severe).
  - Paradoxical abdominal motion (yes/no).
  - Signs of respiratory encephalopathy (sleepiness and/or asterixis and/or confusion) (yes/no).

- No correction or impairment of hypercapnic respiratory acidosis on ABG, that is, one of the following criteria:
  - pH < 7.30 and/or increase in \( PaCO_2 \) of at least 20% as compared with value under NIV.
  - No correction or impairment of hypoxemia: \( SpO_2 \) < 90% and/or \( PaO_2 \) < 60 mm Hg (8 kPa) with standard \( O_2 \) ≥ 5 L/min or \( FiO_2 \) ≥ 0.5 with high flow heated and humidified nasal oxygen.

### Box 2: Predefined criteria for intubation (non-invasive ventilation (NIV) failure)

**Patients will be intubated if, at least, one major or two minor criteria are met:**

#### Major criteria

- Respiratory or cardiac arrest.
- Haemodynamic instability defined as a mean arterial blood pressure (ABP) ≤ 65 mm Hg despite fluid loading (≥ 500 mL) and/or the need of vasoressors.
- Sustained cardiac arrhythmia.
- Ventilatory inefficiency with agitation and/or major air leaks.

#### Minor criteria

- Worsening of acute-on-chronic respiratory failure under NIV with:
  - Respiratory rate > 35/min.
  - pH < 7.20.
  - \( PaO_2 \) (arterial oxygen tension) < 60 mm Hg (8 kPa) with \( FiO_2 \) (inspired fraction of oxygen) > 0.6.
- Neurological impairment (Glasgow Coma Scale < 9).
- Impossibility to clear copious tracheal secretions.
- Organ failure other than respiratory.

---

Ricard J-D, et al. BMJ Open 2018;8:e022983. doi:10.1136/bmjopen-2018-022983
Protocol feasibility
We will undertake a preliminary pilot study in five centres before conducting the full-scale research project. This preparatory phase will last 5 months (including an enrolment period of about 3 months) and seek to recruit approximately 24 patients. We aim to address current uncertainties regarding the feasibility of performing the assessments for switching between NIV and SB according to the study protocol. The outcomes to assess feasibility are described in box 4. The key criterion for evaluating the success of the pilot study is that at least 90% of patients will have valid and complete VFDs data. Failure to reach these criteria does not necessarily indicate unfeasibility; rather, it underlines modifications to be made in the protocol. Data from the pilot phase will be included into the final analysis if no modification has been made in the assessment of the VFDs.9

Statistical considerations
Sample size calculation
The most recent large study dataset on hypercapnic respiratory failure patients comes from the EchoICU trial.10 In that study, mean duration of NIV was 5.2 days. Fifteen per cent of patients failed NIV and required intubation. A total sample size of 242 patients (121 in each group) was determined necessary to detect as statistically significant a decrease of 40% of ventilator support duration in the HFHO group, with a power of 90% and an alpha risk of 0.05. The sample size calculation was based on the following assumptions: mean number of VFDs between day 0 and day 28 of 21.3 in the standard O₂ group, which is congruent with EchoICU trial data8; mortality rate at day 28 of 10%11 and equal in both groups; a loss to follow-up rate of approximately 10%.

Statistical analysis
Data will be analysed using SAS software (V.9.4 or higher). A flow chart will describe the number of eligible patients, the number of patients effectively included in the study and in each of the two groups. Demographic and clinical characteristics of the study patients at baseline and at each follow-up visit will be reported with frequencies and percentages for categorical variables, and with mean, SD, median and IQR for continuous variables. This description will be performed for all patients and for each group. All analysis for the primary and secondary outcomes will be performed in the intention-to-treat population. All tests will be two-sided with a statistical significance of 5%.

Primary outcome analysis
VFDs at 28 days postrandomisation will be compared between the two groups by Wilcoxon-Mann-Whitney two-sample rank-sum test in the intention-to-treat population. A sensitivity analysis will be conducted in the patient population for which the criteria for switching from NIV to SB, or vice versa, are not strictly verified. Imputation methods will be used to replace missing values from the primary outcome. The MICE method ‘Multivariate equation imputation by chain equations’ will be used.

Secondary outcome analyses
Continuous outcomes (including length of hospital stay, duration to reach predefined criteria to stop NIV, duration of NIV and IMV, patient comfort, respiratory rate and dyspnoea assessment score) will be compared between the study groups using Student’s t-test or the Wilcoxon-Mann-Whitney two-sample rank-sum test as appropriate. Dichotomous outcomes (including mortality, intubation, complications related to NIV, complications related to

Figure 1 Ventilatory strategy for the first sequences of NIV and SB (HFHO or standard O₂), according to respective predefined criteria. Patients will follow this cycle according to their allocated group, until weaning from NIV and subsequently from oxygen therapy. ABG, arterial blood gas; HFHO, high flow heated and humidified nasal oxygen; NIV, non-invasive ventilation; SB, spontaneous breathing.
**Subgroup analyses**

A subgroup analysis is planned to analyse whether the treatment effect is modified by pH before randomisation. Another subgroup analysis will investigate whether the treatment effect is modified by a history of NIV use before inclusion into this study. Both analyses will be conducted for the primary outcome (VFDs).

**Patient and public involvement**

The research question was developed thanks to our patients’ input and experience with NIV and nasal high flow. Patients are regularly questioned on the benefits of these techniques regarding comfort and tolerance. Patients’ constant feedback during routine care therefore helped us assess the burden of the intervention and establish the study design. For example, our initial design of the study included evaluation of patients’ respiratory parameters and interruption of NIV during night time. Based on the patients’ feedback—that it would be best for their own comfort, not to be woken up for the assessment—we modified the study protocol, so as to preserve their sleep. Results of the trial will be made available to all participants via ClinicalTrials.gov as well as by email notification.

**TRIAL STATUS**

Recruiting.

**ETHICS AND DISSEMINATION**

**Legal obligations and approval**

Sponsorship has been agreed by Assistance Publique—Hôpitaux de Paris (AP-HP, Clinical Research and Innovation Department) for this minimal risks and constraints human research study. AP-HP has obtained the favourable opinion of the Comité de Protection des Personnes (CPP) Sud-Ouest & Outre-Mer IV (ref CPP17-049a/2017-A01830-53) for the study protocol (version HIGH-FLOW ACRF –01; 17 October 2017). The AP-HP has sent the CPP approval and the summary of the protocol to the Agence Nationale de Sécurité du Médicament et des Produits de Santé for information. The trial will be carried out in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines. Any substantial modification to the protocol must be sent to the sponsor for approval. Once approval has been received from the sponsor, it must also obtain approval from the CPP before the amendment can be implemented. The information sheet and the consent form can be revised if necessary, particularly if there is a substantial amendment to the study or if adverse reactions occur. AP-HP is the owner of the data. The data cannot be used or disclosed to a third party without its prior permission.

**Methods for obtaining information and consent from research participants**

In accordance with Article L.1122-1-1 of the French Public Health Code, no minimal risk and constraints research can be carried out on a person without his/her free and informed consent, obtained expressly after the person has been given the information specified in Article L.1122-1 of
Table 2  Secondary outcome measures

| Key domains to VFDs | Outcome                                                                 | Time frame for assessment                     |
|--------------------|-------------------------------------------------------------------------|------------------------------------------------|
| Duration of NIV sessions (hours) | 28 days postrandomisation                                               |                                                |
| Number of days between the day of initially achieving unassisted ventilation and day 28 postrandomisation (ie, after having successfully spent 48 consecutive hours of unassisted breathing) | 28 days postrandomisation                                               |
| Number of days between the day the patient first meets criteria for NIV cessation and day 28 postrandomisation | 28 days postrandomisation                                               |
| Proportion of patients achieving 48 consecutive hours of unassisted breathing | 28 days postrandomisation                                               |
| Proportion of patients requiring NIV resumption after 48 consecutive hours of unassisted breathing | 28 days postrandomisation                                               |
| Number of NIV sessions | 28 days postrandomisation                                               |

Tolerance/comfort

| Outcome                                                                 | Time frame for assessment                      |
|-------------------------------------------------------------------------|------------------------------------------------|
| Patient self-assessment of comfort during each NIV period measured by VAS (score range 0–10; higher values represent a better outcome) | After 1 hour of NIV, up to 28 days postrandomisation |
| Nurse assessment of comfort during each NIV period measured by Likert scale (score range 1–5; higher values represent a better outcome) | After 1 hour of NIV, up to 28 days postrandomisation |
| Patient self-assessment of comfort during each SB period measured by VAS (score range 0–10; higher values represent a better outcome) | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter, up to 28 days postrandomisation |
| Nurse assessment of comfort during each SB period measured by Likert scale (score range 1–5; higher values represent a better outcome) | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter, up to 28 days postrandomisation |
| Patient self-assessment of dyspnoea during each NIV period measured by VAS (range 0–10; higher values represent a worst outcome) | After 1 hour of NIV, up to 28 days postrandomisation |
| Nurse assessment of dyspnoea during each NIV period measured by Likert scale (score range 1–5; higher values represent a worst outcome) | After 1 hour of NIV, up to 28 days postrandomisation |
| Patient self-assessment of dyspnoea during each SB period measured by VAS (range 0–10; higher values represent a worst outcome) | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days |
| Nurse assessment of dyspnoea during each SB period measured by Likert scale (score range 1–5; higher values represent a worst outcome) | After 2 hours of SB in the 48 first hours, and every 4 hours thereafter, up to 28 days postrandomisation |
| Respiratory rate during NIV periods | After 1 hour of NIV, up to 28 days postrandomisation |
| Respiratory rate during SB periods | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter, up to 28 days postrandomisation |
| Proportion of patients using accessory muscles during NIV periods | After 1 hour of NIV, up to 28 days postrandomisation |
| Daily ABGs (in terms of pH, PaCO2, and PaO2 measured between 8:00 and 10:00) | Up to 28 days postrandomisation |
| Proportion of patients with premature NIV cessation (intolerance, defined by agitation and/or mask removal, and/or patient’s wish to interrupt session before) | 28 days postrandomisation |
| Proportion of patients refusing to resume NIV (despite meeting criteria) | 28 days postrandomisation |
Table 2 Continued

| Key domains          | Outcome                                                                 | Time frame for assessment                          |
|----------------------|-------------------------------------------------------------------------|-----------------------------------------------------|
| Proportion of patients who need secondary intubation and IMV | 28 days postrandomisation                                               |
| Proportion of patients who need secondary intubation and IMV | 28 days postrandomisation                                               |
| **Side effects**     |                                                                         |                                                     |
| Proportion of patients with nasal bridge ulceration          | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with facial skin erythema and/or ulceration | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with eye irritation                    | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with nasal congestion                  | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with nasal/oral dryness                | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with gastric distension                 | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with nosocomial pneumonia               | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with pneumothorax                       | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with arterial hypotension               | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with nostril ulceration (including nasolabial angle, columella, nostril sill) | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| Proportion of patients with nose bleeding                      | After 2 hours of SB in the first 48 hours, and every 4 hours thereafter; and after 1 hour of NIV; up to 28 days postrandomisation |
| **Hospital length of stay**                                   |                                                                         |                                                     |
| Overall hospital length of stay (defined as the duration from hospital admission to hospital discharge) | 28 days postrandomisation                                               |
| Length of stay in the unit where the patient has been first admitted (either ICU, intermediate care or respiratory care unit) | 28 days postrandomisation                                               |
| Length of stay in the units where the patient has received NIV | 28 days postrandomisation                                               |
| **Mortality**                                                  |                                                                         |                                                     |
| All-cause mortality                                           | 28 days postrandomisation                                               |
| All cause in-hospital mortality                               | 28 days postrandomisation                                               |

Continued
said Code. For both organisational and practical reasons, we will seek oral rather than written consent. The person will be given 15 min between receiving the information and being asked to give their consent. The person’s free and informed oral consent will be obtained by the principal investigator or a physician representing the investigator, a maximum 1 hour after being admitted to the service.

Emergency inclusions will be allowed in this research protocol, in accordance to the Public Health Code, article L1122-1-2. The patient and legal representative will be informed as soon as possible, and a written informed consent will be required for the pursuit of this research. The patient and legal representative will have the right to oppose to the use of his data in the research. For patients who are not able to sign the informed consent form, the consent may be obtained, in descending order of priority, from a legal representative, family member or a close relative, if they are present. The investigator will specify in the research participant’s medical file the methods used for obtaining their consent, as well as the methods used for providing information to obtain consent. The investigator will retain the original signed and dated consent form.

**Data collection and quality control**

The persons responsible for the quality control of clinical matters will take all necessary precautions to ensure the confidentiality of information relating to the study participants. These persons, as well as the investigators themselves, are bound by professional secrecy. During or after the research, all data collected about the participants and sent to the sponsor by the investigators (or any other specialised collaborators) will be anonymised. Under no circumstances should the names and addresses of the subjects involved be shown.

In any case of premature withdrawals and exits, the investigator must document their reason(s) and try to collect primary endpoint, secondary endpoints and safety assessment, if the participant agrees. If a participant exits the study prematurely or withdraws consent, any data collected prior to the date of premature exit may still be used, excepted if the participant refuse in writing.

A data monitoring committee (DMC) is not required for this research with minimal risks for the following reasons: (1) the devices have been used in routine for many years, and so we have enough perspective regarding their safety; (2) none of the three international experts who reviewed the protocol during the funding application process stressed the need for a DMC and (3) according to the French law, research with 'minimal risks' does not require a DMC. The research data will be collected and monitored using an eCRF through CleanWEB Electronic Observation Book and will be centralised on a server hosted by the AP-HP Operations Department. This research is governed by the CNIL ‘Reference Method for processing personal data for clinical studies’ (MR-001, amended). AP-HP, the sponsor, has signed a declaration of compliance with this ‘Reference Method’.

Research staff of the URC will work with local investigators to obtain data that are as complete and accurate as possible. An independent Clinical Research Associate

### Table 2  Continued

| Key domains | Outcome | Time frame for assessment |
|-------------|---------|---------------------------|
|             | All cause inpatient mortality in the unit where the patient has been first admitted (either ICU, intermediate care or respiratory care unit) | 28 days postrandomisation |
|             | All cause inpatient mortality in the unit where the patient has been transferred to further receive NIV (eg, from ICU to intermediate care for those who provide NIV in intermediate care) | 28 days postrandomisation |

ABG, arterial blood gas; ICU, intensive care unit; IMV, invasive mechanical ventilation; NIV, non-invasive ventilation; PaCO₂, alveolar carbon dioxide tension; PaO₂, arterial oxygen tension; SB, spontaneous breathing; VAS, Visual Analogue Scale; VFDs, ventilator-free days.
appointed by the sponsor will be responsible for the proper running of the study, for collecting, documenting, recording and reporting all handwritten data, in accordance with the Standard Operating Procedures applied within the Clinical Research and Innovation Department of AP-HP. The investigators agree to accept the quality assurance audits carried out by the sponsor as well as the inspections carried out by the competent authorities. All data, documents and reports may be subject to regulatory audits. These audits and inspections cannot be refused on the grounds of medical secrecy. An audit can be carried out at any time by independent individuals appointed by the sponsor. The aims of the audits are to ensure the quality of the study, the validity of the results and compliance with the legislation and regulations in force. The persons who manage and monitor the study agree to comply with the sponsor’s audit requirements. The audit may encompass all stages of the study, from the development of the protocol to the publication of the results and the storage of the data used or produced as part of the study. Sponsor is responsible for access to the study database.

**Safety considerations**

During this research, adverse events (serious (SAE) and non-serious) do not need to be reported to the sponsor. The report must instead be made as part of the vigilance procedure applicable to the intervention under investigation. However, the investigator will report SAE and non-serious adverse event in the ‘Adverse events’ section of the e-CRF. The following events are foreseen, expected SAEs:

- SAE associated with the use of NIV:
  - Pneumothorax.
  - Stopping NIV for intolerance/agitation leading to intubation.
- SAE potentially associated with the use of HFHO:
  - Pneumothorax (this is only theoretical, as it has never been described).
- SAEs that are not specifically linked to the experimental protocol but are the result of the progression of the disease:
  - Worsening of hypoxemia or worsening of hypercapnia requiring intubation and IMV.
  - Cardiovascular event (cardiac arrest, myocardial ischaemia, supraventricular or ventricular abnormal cardiac rhythm).
  - Initiation of IMV (except for those situations where the investigator believes there is a link between the SAE and the experimental protocol).
  - Nosocomial pneumonia, ventilator-associated pneumonia.
  - Occurrence of organ failure or septic shock.
  - Death related to the progression of the disease that led the patient to the ICU, intermediate care or respiratory care unit.
  - Death related to the progression of a chronic disease mentioned in the patient’s medical history.
- Death resulting from a decision of withholding or withdrawing life support.

**Dissemination of results**

Findings will be disseminated through national and international scientific conferences, and publication in peer-reviewed journals. The results of the trial will be relevant to intensivists who manage patients with hypercapnic ARF.

**DISCUSSION**

To date, NIV is the cornerstone of hypercapnic ARF ventilatory support, and standard O₂ is used in-between breaks of NIV. Because of several drawbacks regarding its characteristics (absence of positive end-expiratory pressure, cold and not humidified, and limited flow), standard O₂ may not be the best delivery mode to maintain the beneficial effects obtained during NIV periods. HFHO has shown its unambiguous benefits during hypoxemic respiratory failure, many of its features may apply to hypercapnic respiratory failure.

This trial is—to the best of our knowledge—the first RCT that will assess the use of HFHO in patients with hypercapnic ARF. To date, outside case reports in patients with hypercapnic ARF, the only data available on HFHO in this indication has been obtained from small series of stable patients with COPD. These observational studies have consistently shown that HFHO is feasible, well accepted and exerts beneficial effects in patients with severe but stable COPD. Improvements have been measured in respiratory rate, tidal volume, rapid shallow breathing index, PaCO₂, and end-expiratory lung volume, all suggesting that HFHO enables a certain decrease in the work of breathing in these patients.

A randomised cross-over trial has confirmed improvement in respiratory parameters in stable patients with COPD. In the acute setting of hypoxic respiratory failure, one study has shown that HFHO was better tolerated than NIV when used sequentially. When specifically addressing the breaks in-between NIV sessions, one single RCT has evaluated HFHO in the setting of ARF. It planned to enrol 70 patients with ARF requiring NIV. Patients were randomised to receive either standard O₂ or HFHO in-between NIV sessions. In this study, the primary endpoint was the time spent without NIV. Secondary endpoints included respiratory variables, a dyspnoea score and patients’ comfort. To date, preliminary results have been published under abstract form, for the first 44 patients. No difference was found for the primary outcome. Similarly, respiratory variables did not differ. However, dyspnoea and comfort were significantly improved with the use of HFHO. There are, however, several limitations that need to be acknowledged: (1) the number of patients is relatively small; (2) the study was not limited to hypercapnic patients (only a small number of patients with COPD among the first 44 patients included) and (3) there was significantly more patients with hypoxemic ARF in those allocated to HFHO; these patients may have required longer NIV treatment. In the context
of hypoxic ARF, a recent retrospective study showed that patients with chronic lung disease and treated with HFHFO had similar outcomes compared with those without a history of chronic lung disease.9 Taken together, these data suggest that patients with hypercapnic ARF could also benefit from this technique.

**Strengths and limitations**

This is the largest prospective multicentre RCT comparing standard O2 to HFHFO in the field of hypercapnic ARF. Very strict criteria to initiate, stop and resume NIV will be used to ensure that all centres will apply the technique similarly. A consensus on these criteria has been reached through a two-round Delphi survey. A pilot study will assess the feasibility of these criteria for the trial. Regarding the blinding, because of the nature of the study and the devices evaluated, it is not possible to blind patients nor the investigators to the allocation group. However, all the analyses will be carried out in a blinded manner.

In conclusion, the ‘High Flow-ACRF’ trial is an investigator-initiated RCT empowered to test the hypothesis that HFHFO in comparison to standard O2 in-between breaks of NIV sequences may increase the number of VFDs in patients with hypercapnic ARF. Its results could be very useful for optimising ACRF management with NIV in clinical practice.

**Author affiliations**

1Service de Réanimation Médico-Chirurgicale, AP-HP, Hôpital Louis Mourier, Colombes, France  
2INSERM, IAME, UMR 1137, Paris, France  
3Université Paris Diderot, IAME, Paris, France  
4Département Épidémiologie, Biostatistiques et Recherche Clinique, Hôpital Bichat - Claude-Bernard, Paris, France  
5INSERM, CIC-EC 1425, Paris, France  
6INSERM, ECEVE, UMR 1123, Paris, France  
7Department of Medical Intensive Care, Charles Nicolle University Hospital, Rouen University, Rouen, France  
8UNIROUEN, EA3830-GRHV, Normandie University, Institute for Research and Innovation in Biomedicine(INSERM), Rouen, France

**Collaborators**

From the REVA network: Stephan Ehrmann (Tours), Alain Mercat (Angers), Alexandre Demoule (Paris), Muriel Farbouch (Paris), Benjamin Strynm (Clamart), Jack Richerocue (Beauvais), Claude Guerin (Lyon), Jean Reignier (Nantes), Saad Reis (Lilles), Arnaud Thille (Poitiers), Eran, ’Her (Brest), Thierry Boullain (Orléans), Jean-Philippe Rigaud (Dieppe), Antoine Cuvellier (Rouen), Kaldoun Kutefian (Mulhouse), Sandrine Jafre (Nantes), Armand Meckosno (Dessap (Créteil), Jean-Christophe Callahan (Le Mans), Jean-Claude Lacherde (La Roche sur Yon), Jean-Michel Constant (Clermont-Ferrand), Gilles Capeller (Besançon), Emmanuel Antok (St-Pierre), Sarah Heili (Colombes) / Lisel Piquidoul (Lauzanne).

**Contributors**

Trial design development: J-DR, CG, FD and JM. Design of the statistical analysis plan: FD and ME-F. Drafting of the present manuscript: FD and J-DR. All authors have contributed and approved this manuscript.

**Funding**

This work was supported by French Ministry of Health (Programme de Recherche Clinique 2016 (PHRC), project no: PHRON-16-0383), Fisher & Paykel will supply Airvo2 devices, necessary equipments and consumables and covered the costs of the two foreign centres not covered by the PHRC.

**Competing interests**

J-DR, JM and CG had travel and accommodation expenses to attend scientific meetings covered by Fisher & Paykel.

**Patient consent**

Obtained.

**Ethics approval**

Comité de Protection des Personnes (CPP) Sud-Ouest & Outre-Mer IV.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

We envisage no additional data that would not be published.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1. Ford ES, Croft JB, Mannino DM, et al. COPD surveillance–United States, 1999–2011. *Ches* 2013;14:284–305.
2. Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. *Thorax* 2016;71:i1–i35.
3. Schnell D, Timstra JT, Darmon M, et al. Noninvasive mechanical ventilation in acute respiratory failure: use in outcomes and evidence. *Intensive Care Med* 2014;40:582–91.
4. Demoule A, Chevet S, Carlucci A, et al. Changing use of noninvasive ventilation in critically ill patients: trends over 15 years in francophone countries. *Intensive Care Med* 2016;42:82–92.
5. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxic respiratory failure. *N Engl J Med* 2015;372:2185–96.
6. Spoletini G, Aloiabi M, Blasi F, et al. Heated humidified high-flow nasal oxygen in adults: mechanisms of action and clinical implications. *Ches* 2015;148:523–61.
7. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200.
8. Schoenfeld DA, Bernard GR. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. *Crit Care Med* 2002;30:1772–7.
9. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. *BMJ Med Res Methods* 2010;10:1.
10. Jolliet P, Besbes L, Abroug F, et al. An international phase iii randomised trial on the efficacy of heliox/oxygen during spontaneous breathing and intermittent non-invasive ventilation for severe exacerbations of chronic obstructive pulmonary disease (the e.c.h.o.icutrial). *Intensive Care Med Exp* 2015;3:4422.
11. Maggiore SM, Riches JC, Abroug F, et al. A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. *Crit Care Med* 2010;38:145–51.
12. Lepere V, Mesuika J, La Combe B, et al. High-flow nasal cannula oxygen supply as treatment in hypercapnic respiratory failure. *Am J Emerg Med* 2016;34:1914.e1–1914.e2.
13. Bräunlich J, Beyer D, Mai D, et al. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. *Respiration* 2013;95:319–25.
14. Bräunlich J, Seyfarth HJ, Wirtz H. Nasal High-flow versus non-invasive ventilation in stable hypercapnic COPD: a preliminary report. *Multidiscip Respir Med* 2015;10:27.
15. Bräunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2016;11:1077–85.
16. Pisani L, Fasano L, Corcione N, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow oxygen therapy in stable hypercapnic COPD. *Thorax* 2017;72:373–5.
17. Fraser JP, Spooner AJ, Dunster KR, et al. Nasal high flow oxygen therapy in patients with COPD reduces respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised crossover trial. *Thorax* 2016;71:759–61.
18. Frat JP, Broggiere B, Ragot S, et al. Sequential application of oxygen therapy via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: an observational pilot study. *Respir Care* 2015;60:170–8.
19. Spoletini G, Mega C, Khoja A, et al. Better comfort and dyspnea scores with high-flow nasal cannula (HFNC) vs standard oxygen (SO2) during breaks off noninvasive ventilation (NIV). *European Respiratory Society* 2015;OA505.
20. Seo KW, Ahn JJ, Jegal Y, et al. High-flow nasal cannula oxygen therapy for acute hypoxic respiratory failure in patients with chronic lung disease in terms of hospitalization. *Intensive Care Med* 2018;44:387–8.